June 2025, Suzhou – Suzhou SmartNuclide Biopharma Co., Ltd. announced that it will present the first clinical trial data for [⁶⁸Ga]Ga-SNA014 at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, held from June 21-24, 2025, in New Orleans, USA. The study results cover gastric cancer, gastroesophageal junction cancer, and pancreatic cancer.

The study is led by Principal Investigators Professor Miaoli Yan, President of The First Affiliated Hospital of Soochow University, and Professor Songbing Qin, Director of the Department of Radiation Oncology. The data will be presented by Dr. Yan Wang.

Presentation Details:

Title: A FIH of [68Ga]Ga-SNA014, a Novel Nanobody PET Tracer for CLDN18.2-Expressing Solid Tumors

Abstract No.: 1042

Report form: Oral Presentation

Session: SS23 Oncology Discovery and Translational

Date: Monday, June 23, 2025

Time: 12:45 PM – 2:00 PM

Reporter: Dr. Wang, First Affiliated Hospital of Soochow University

SNA014 is a ⁶⁸Gallium-labeled single-domain antibody targeting Claudin18.2, acting as a radiotracer with broad application potential in solid tumors such as Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJ) and pancreatic cancer.

Data from this first-in-human (FIH) study indicate that [⁶⁸Ga]Ga-SNA014 exhibits very low uptake in normal organs like blood and kidneys. In contrast, it demonstrates high uptake and prolonged retention in tumors of gastric/GEJ adenocarcinoma and pancreatic cancer. These findings suggest a wide therapeutic window for the agent, providing critical insights for the future clinical development of its therapeutic counterparts, [¹⁷⁷Lu]Lu-SNA014 and [²²Ac]Ac-SNA014.

About SNMMI

The Society of Nuclear Medicine & Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, notably through its educational and research initiatives. Founded in 1954, SNMMI brings together professionals from all subspecialties within the field. The Society is committed to driving innovation, establishing practice standards, enhancing education in precision medicine, and improving patient care through advanced imaging and therapeutics.

The SNMMI Annual Meeting is the premier educational, scientific, research, and networking event in nuclear medicine and molecular imaging. This four-day meeting, held each June, provides physicians and researchers with a platform to delve into the latest advancements and explore their practical clinical applications. The 2025 SNMMI Annual Meeting will take place from June 21-24 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA.